Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients

ASCO 2022: Highlights and analysis

Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients

ASCO 2022: Breast cancer highlights

ASCO 2022: Latest in prostate cancer, including PARP inhibitors

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC